Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553041 · ClinicalTrials.gov registry record · Early Phase 1
18F-Fluciclovine PET-MRI in High-grade Glioma
A Early Phase 1 study of Glioma and High Grade Glioma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05553041 is a Early Phase 1 study of Glioma and High Grade Glioma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 30 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05553041, a Early Phase 1 study of Glioma and High Grade Glioma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.
Conditions Studied
Interventions
- DRUG 18F-Fluciclovine PET-MRI
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553041
The ClinicalTrials.gov registry entry for NCT05553041 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluciclovine PET-MRI is the first listed.
NCT05553041 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05553041 about?
NCT05553041 is a clinical study titled "18F-Fluciclovine PET-MRI in High-grade Glioma". The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes tha...
What is the current status of trial NCT05553041?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-08-07. Estimated completion is 2027-12.
What conditions does trial NCT05553041 study?
This clinical trial studies the following conditions: Glioma, High Grade Glioma, Glioma, Malignant, Diffuse Glioma, Glioma Intracranial.
What interventions are being tested in trial NCT05553041?
The interventions under investigation include: 18F-Fluciclovine PET-MRI (DRUG).
Who is sponsoring clinical trial NCT05553041?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05553041 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
-
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.